Merck partially regains its breakthrough tag for hep C combo

Merck ($MRK) execs weren't happy when the FDA stripped its breakthrough therapy designation for their closely watched hepatitis C combo. But the agency has now relented--at least partly. The pharma giant said it's getting two new BTD titles in small subgroups of patients to replace the broader breakthrough tag that it lost. Report

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.